Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Kenvue stock on February 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
- Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
- Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
- Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
- Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
- Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
- Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
- Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
- Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
- Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.
Kenvue Stock Performance
KVUE stock traded down $0.28 during mid-day trading on Thursday, hitting $17.38. The company had a trading volume of 26,380,202 shares, compared to its average volume of 47,391,695. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The firm has a market cap of $33.30 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 4.11 and a beta of 0.51. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The stock’s fifty day moving average price is $17.89 and its two-hundred day moving average price is $17.35.
Kenvue Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s payout ratio is currently 107.79%.
Analyst Ratings Changes
KVUE has been the subject of several research reports. Canaccord Genuity Group increased their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. UBS Group lifted their price objective on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Finally, Barclays increased their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Friday, March 6th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.58.
Read Our Latest Research Report on KVUE
Institutional Trading of Kenvue
Institutional investors have recently added to or reduced their stakes in the stock. Salomon & Ludwin LLC purchased a new stake in shares of Kenvue in the third quarter worth about $25,000. NBT Bank N A NY boosted its stake in Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after buying an additional 1,006 shares during the period. Cornerstone Planning Group LLC increased its stake in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. raised its holdings in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of Kenvue during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Insider Activity at Kenvue
In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.68% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
- Five stocks we like better than Kenvue
- The $20 Trillion Discovery Beneath the Waves
- The largest IPO in history is coming
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- Only 500 people today…
- Central banks just did something they haven’t done since 1967
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
